Each year the RADARS® System Annual Scientific Meeting strives to connect industry, academia, and regulatory experts to discuss the latest trends in prescription drug abuse, misuse, and diversion. This year we focus on Surveillance of Psychoactive Drugs: Opioids, Psychedelics, and Cannabinoids. We hope you enjoy the presentations and engage in lively discussions, particularly with our esteemed guest speakers.

The RADARS® System continues to be thankful for our outstanding partners, including those of you joining us for this year’s meeting. We would like to express our sincere appreciation for your continued support.

**11:00 am–11:45 am EDT**  
**Surveillance of Psychoactive Drugs: Opioids, Psychedelics, and Cannabinoids**  
*Richard C. Dart, MD, PhD*  
Recognition of prescription drug abuse continues to expand and evolve. RADARS® System is evolving to provide rapid and accurate data for prescription drug misuse of all types. This presentation reviews RADARS® System data and sets the stage for subsequent discussions about the remarkably diverse set of psychoactive drugs abused in the United States, Europe, and Canada.

**11:45 am–12:15 pm EDT**  
**Application of Systems Science in Opioid Misuse to Psychedelic Drugs**  
*Mohammad S. Jalali, PhD*  
The objectives of this talk are to 1) introduce the concept of systems science and its application in understanding the complexities of substance use disorders, specifically in the context of opioid misuse, and how similar applications can be conducted for the emerging field of psychedelic medicine, and 2) discuss the challenges and opportunities associated with the applications of systems science, including the need for interdisciplinary collaboration and the development of more comprehensive and personalized treatment approaches.
Surveillance of Psychoactive Drugs
Opioids, Psychedelics, and Cannabinoids

12:15 pm–12:45 pm EDT
Policy Suggestions to Support the Safe Uses of Psychedelics
Brian Anderson, MD, MSC
The objectives of this talk are to provide a brief discussion on the historical use of psychedelic medicines, the status of the empirical evidence, and the policy considerations that must be considered for this complex topic. This talk will also provide suggestions for how public health and harm reduction can be supported by multi-disciplinary stakeholders to create and disseminate best practices and public policies.

12:45 pm–1:15 pm EDT
Cannabis: Lessons Learned from the Public Experience in Colorado
Mike Van Dyke, PhD, CIH
This talk will describe the 1) available public health monitoring tools and datasets for recreational cannabis use, 2) public health lessons learned in legalizing cannabis, and 3) the current limitations of cannabis public health surveillance and how it might be improved.

1:15 pm–1:45 pm EDT
Psychoactive Drugs & Fixing the Evidence Generation System, a Fireside Chat
Robert M. Califf, MD, moderated by Richard C. Dart, MD, PhD
Dr. Califf recently published a perspective paper stating the US Food and Drug Administration (FDA) plays a critical role in improving the evidence generation and dissemination system. In this Fireside Chat, Dr. Califf will share his thoughts about fixing the evidence generation system as it pertains to the surveillance of psychoactive drugs.

1:45 pm–1:55 pm EDT
Break

1:55 pm–2:25 pm EDT
Assessing Polysubstance Use of Licit (Gabapentin, Xylazine) and Illicit Substances
Sandra Comer, PhD
This talk will explain the risks associated with psychoactive polysubstance use, describe new observations with gabapentin and xylazine polysubstance use, and describe how we assess and respond to the evolution of polysubstance abuse.
Surveillance of Psychoactive Drugs
Opioids, Psychedelics, and Cannabinoids

2:25 pm–2:45 pm EDT
Defining Polysubstance Use in a National Population-based Survey
Karilynn Rockhill, MPH
This talk will investigate the definition of polysubstance use to include both all prescription drug use and recreational substance use, and will characterize present day polysubstance use patterns in the general adult population to define unique behavioral risk profiles and quantity their prevalence.

2:45 pm–3:25 pm EDT
Satisfying the Craving for Novel Psychoactive Post-Market Surveillance
Andrew Monte, MD, PhD
This talk will identify surveillance differences for drugs with regional legal status differences, identify gaps in data collection tools, and discuss new tools to fill these gaps.

3:25 pm–4:00 pm EDT
Panel Discussion and Summary
Moderator: Richard C. Dart, MD, PhD